Dr. Park CDMO Partners With Thermo Fisher Scientific To Equip State-Of-The-Art Viral Vector Manufacturing Facility

Thermo Fisher Scientific Inc., the world leader in serving science, announced that Dr. Park, an emerging viral vector contract development and manufacturing organization (CDMO) based in South Korea, has chosen Thermo Fisher to supply advanced bioreactors and consumables for its newest facility. Dr. Park focuses on Adeno-associated virus (AAV)-based viral vector production and currently operates at a scale of 5,000 liters per batch, producing up to 40 clinical-grade batches annually. 

The company inaugurated its new Phase 1 facility on August 5, 2025, with the goal of achieving cGMP certification in 2026. This facility is intended to expand access to cell and gene therapies globally, with future plans to increase capacity to 10,000 liters per batch. To support these plans, Dr. Park has integrated multiple solutions from Thermo Fisher’s portfolio into the new facility. These include the Thermo Fisher Scientific™ HyPerforma™ 1,000 L Single-Use Bioreactor, Thermo Scientific™ Nunc™ Automated Cell Factory Manipulator, and Thermo Scientific™ DynaSpin™ Single-Use Centrifuge.

Daniella Cramp, Senior Vice President and President, BioProduction at Thermo Fisher Scientific, stated, “We are proud to collaborate with Dr. Park CDMO as they advance viral vector manufacturing in South Korea. By providing our reliable and scalable bioprocessing solutions, we aim to speed up development and delivery of cell and gene therapies to patients who need them.”

Yong-Ho Park, CEO, Dr. Park, mentioned, “Our collaboration with Thermo Fisher Scientific has been instrumental in equipping our new facility with advanced bioproduction capabilities. Their cutting-edge technologies and deep expertise are critical enablers of our long-term vision and will strengthen our ability to serve customers globally.”

Tony Acciarito, President, Asia Pacific and Middle East, Africa at Thermo Fisher Scientific, said in a statement, “Collaboration is essential in advancing scientific innovation and bringing new therapies to patients. Our work with Dr. Park CDMO reflects a shared commitment to building robust manufacturing capabilities in South Korea and across the region. By working together, we can progress cell and gene therapies and support the evolving needs of the industry.” 

These technologies are designed to optimize upstream and downstream workflows, reduce manual interventions, and support efficient scale-up from clinical to commercial production. By enhancing automation and process control, the solutions aim to improve scalability, consistency, and efficiency while meeting the highest standards of safety, quality, and regulatory compliance.

The collaboration between Thermo Fisher and Dr. Park highlights the growing significance of advanced viral vector manufacturing as cell and gene therapies move beyond research into clinical and commercial applications. Robust infrastructure and innovative technologies are increasingly vital to accelerate development timelines and ensure broader patient access to transformative treatments in the rapidly expanding gene therapy landscape.